ORKA Oruka Therapeutics, Inc.
Price Chart
Executive Summary
Oruka Therapeutics amended its IL-23 license agreement with Paragon Therapeutics to expand the field of use to include inflammatory bowel disease (IBD), removing a key restriction on ORKA-001's addressable market. The amendment imposes dosing restrictions (no monotherapy IBD dosing until June 2030, no combination dosing until June 2028), but these accelerate to June 2028 upon a material transaction like a change of control. This significantly expands the commercial opportunity for ORKA-001, a $3.5B market cap biotech's lead asset.
Actionable Insight
This is a material pipeline expansion for ORKA-001 into IBD, a large and competitive market with established IL-23 blockbusters (Skyrizi, Stelara). The dosing restrictions create a clear timeline catalyst: watch for IND filings or Phase I starts in IBD after June 2028. The change-of-control acceleration clause also makes Oruka a more attractive M&A target.
Key Facts
- Oruka expanded the field of use for its IL-23 license to include all therapeutic areas, including inflammatory bowel disease (IBD), which was previously excluded.
- Monotherapy dosing of ORKA-001 for IBD is restricted until June 1, 2030; combination dosing until June 1, 2028.
- Upon a material transaction (change of control or sale of Phase II-stage assets), the monotherapy restriction accelerates to June 1, 2028.
- Paragon granted Oruka exclusivity in the IBD field until October 11, 2029, and Oruka granted Paragon a non-exclusive cross-license for retained antibodies outside IBD.
- The amendment was signed May 29, 2026, and filed June 1, 2026.
Financial Impact
No financial terms disclosed; the amendment expands the addressable market for ORKA-001 to include IBD, a multi-billion-dollar therapeutic area.
Risk Factors
- IBD market is highly competitive with approved IL-23 inhibitors (Skyrizi, Stelara, Tremfya) — ORKA-001 must differentiate on efficacy, safety, or dosing.
- Dosing restrictions delay IBD clinical development until at least 2028, limiting near-term value inflection.
- No financial consideration disclosed — the amendment's value depends entirely on ORKA-001's clinical profile in IBD, which is unproven.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-063481 |
| Document: ea029287601ex10-1.htm | 0001213900-26-063481 |
| Document: 0001213900-26-063481-index-headers.html | 0001213900-26-063481 |
| Document: 0001213900-26-063481-index.html | 0001213900-26-063481 |
| Document: 0001213900-26-063481.txt | 0001213900-26-063481 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
1d ago
|
Institutional Cluster
| $63.94 awaiting T+1 | awaiting T+1 | — | $69.89 (+9.31%) |
|
Jun 1, 2026
11d ago
|
8-K
| $55.23 $57.20 | ▲ +3.57% | ▲ +4.26% | $69.89 (+26.54%) |
|
May 22, 2026
21d ago
|
Insider Cluster
| $59.06 $57.99 | ▼ −1.81% | ▼ −1.82% | $69.89 (+18.34%) |
|
May 18, 2026
25d ago
|
Insider Cluster
| $57.50 $60.67 | ▲ +5.51% | ▲ +4.47% | $69.89 (+21.55%) |
|
Apr 28, 2026
6w ago
|
Press Release
| $68.10 $68.10 | · 0.00% | ▲ +1.02% | $69.89 (−2.63%) |
|
Apr 27, 2026
6w ago
|
424B5
| $73.99 $69.49 | ▲ +6.08% | ▲ +6.07% | $69.89 (+5.54%) |
|
Apr 27, 2026
6w ago
|
Press Release
| $73.99 $69.49 | ▲ +6.08% | ▲ +6.07% | $69.89 (+5.54%) |
|
Apr 27, 2026
6w ago
|
8-K
| $76.39 $73.99 | ▼ −3.14% | ▼ −2.66% | $69.89 (−8.51%) |
|
Apr 17, 2026
8w ago
|
DEFA14A
| $68.87 $69.00 | ▲ +0.19% | ▲ +0.84% | $69.89 (+1.48%) |
|
Apr 15, 2026
8w ago
|
144
| $67.07 $68.92 | ▲ +2.76% | ▲ +1.54% | $69.89 (+4.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access